Clinical Trial

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.
Trial Details
NCT Number NCT07069335
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Ovarian Cancer
Enrollment 24 participants
Start Date 2025-06-17
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-16